Product Information
PRAMIPEXOLE 0.125 MG TABLET is a generic product labeled by Strides Pharma Inc., priced at $0.0394 per EA under NDC 64380074605. Its NADAC has been published 282 times since May 12, 2021.
FDA first approved this application on Jun 3, 2014. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
.125 mg/1
Manufacturer
Strides Pharma Inc.NDC
64380074605
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
PRAMIPEXOLE DIHYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA202702FDA Approved
6/3/2014
TE Code
AB
On Market Since
2/15/2021
Pharmacological Classes
Price Statistics
The NADAC for PRAMIPEXOLE 0.125 MG TABLET has been published 282 times since May 12, 2021, and over the history we have for it it has declined 21.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0394 per EA |
|---|---|
| All-time high | $0.0595 (Jan 12, 2022) |
| All-time low | $0.0350 (Nov 20, 2024) |
| 52-week high | $0.0425 |
| 52-week low | $0.0394 |
| Median price | $0.0477 |
| Average price | $0.0476 |
| Largest weekly change | +23.8% (Aug 21, 2024) |
| Weeks tracked | 282 |
| Tracking since | May 12, 2021 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the pramipexole dihydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Strides Pharma Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
pramipexole dihydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nonergot Dopamine Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PRAMIPEXOLE 0.125 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for PRAMIPEXOLE 0.125 MG TABLET, manufactured by Strides Pharma Inc., is $0.0394 per EA (NDC 64380074605), effective Sep 30, 2026.
How has the price of PRAMIPEXOLE 0.125 MG TABLET changed over time?
Over the history we have for it, the NADAC for PRAMIPEXOLE 0.125 MG TABLET has declined 21.2%. It has been tracked across 282 weekly CMS publications since May 12, 2021.
What are the highest and lowest recorded NADAC prices for PRAMIPEXOLE 0.125 MG TABLET?
Since May 12, 2021, the NADAC for PRAMIPEXOLE 0.125 MG TABLET has ranged from a low of $0.0350 (Nov 20, 2024) to a high of $0.0595 (Jan 12, 2022), with a median of $0.0477 per EA.
Are there cheaper alternatives to PRAMIPEXOLE 0.125 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of PRAMIPEXOLE 0.125 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures PRAMIPEXOLE 0.125 MG TABLET?
PRAMIPEXOLE 0.125 MG TABLET (NDC 64380074605) is labeled by Strides Pharma Inc., and CMS classifies it as a generic product.